INT166759

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.37
First Reported 2010
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 2
Total Number 2
Disease Relevance 0.87
Pain Relevance 0.31

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular region (NMS)
Anatomy Link Frequency
muscles 2
NMS (Rattus norvegicus)
Pain Link Frequency Relevance Heat
cINOD 1 96.30 Very High Very High Very High
Inflammation 1 96.06 Very High Very High Very High
Pain 6 88.04 High High
deep brain stimulation 4 50.00 Quite Low
Disease Link Frequency Relevance Heat
Neuroleptic Malignant Syndrome 5 100.00 Very High Very High Very High
INFLAMMATION 1 96.06 Very High Very High Very High
Spasticity 2 95.20 Very High Very High Very High
Pain 2 88.04 High High
Muscular Spasm 2 86.88 High High
Disease 2 50.00 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The reasons for such a range of symptoms observed is due to the multifactorial etiology of the NMS, including preoperative vulnerability, changes in dopaminergic medications, surgical and stimulation effects, underlying PD-related factors and psychosocial effects.
Negative_regulation (effects) of Localization (etiology) of NMS
1) Confidence 0.37 Published 2010 Journal Rev Neurol Section Body Doc Link 20205149 Disease Relevance 0.07 Pain Relevance 0
The objective of this study was to formulate stable and controlled release microparticles for simultaneous delivery and UV spectrophotometric detection in combined dosage of an non-steroidal anti-inflammatory drug (NSAID) (nimesulide, NMS) and a spasmolytic agent (tizanidine, TZN) to maintain plasma concentration that may increase patients compliance, improved therapeutic efficacy, The aim was also to reduce severity of upper GI side effects of NMS because of alteration in delivery pattern via slow release of drug from microparticles and to increase the benefits of spasticity and disability for spastic patients by administering TZN in a modified release formulation as these two drugs are often prescribed in combination for the management of pain associated with muscles spasm.
Negative_regulation (reduce) of Localization (severity) of NMS in muscles associated with pain, spasticity, inflammation, neuroleptic malignant syndrome, cinod and muscular spasm
2) Confidence 0.24 Published 2010 Journal Acta Pol Pharm Section Abstract Doc Link 20524433 Disease Relevance 0.81 Pain Relevance 0.31

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox